Govindarajan Ramprakash, Nagarsenker Mangal S
Bombay College of Pharmacy, Kalina, Santacruz (E), Mumbai 400098, India.
J Pharm Pharmacol. 2004 Jun;56(6):725-33. doi: 10.1211/0022357023538.
We have investigated the influence of processing variables on the solid-state of a model drug, flurbiprofen, in cyclodextrin-based systems and its effect on dissolution behaviour of the drug. The interaction between flurbiprofen and hydroxypropyl beta-cyclodextrin (HP-beta-CyD) was studied by NMR spectroscopy and phase solubility studies. Binary systems containing flurbiprofen and HP-beta-CyD or povidone (polyvinylpyrrolidone) K30, prepared by various processes, were characterized by FTIR, DSC, XRD and dissolution studies. HP-beta-CyD enhanced the solubility of flurbiprofen and increased dissolution rates from binary systems. It was found to be superior to povidone K30 in producing higher dissolution rates. The method of preparation of the binary systems and the agents used were found to have a major influence on the final solid-state of flurbiprofen. Solvents and processing conditions favouring greater interaction between flurbiprofen and the cyclodextrin during the preparation process resulted in greater extent of drug-cyclodextrin association and/or greater amorphization of the drug. Use of ammonia during the preparation of binary systems yielded solids from which very rapid drug dissolution was achieved, due to a higher extent of molecular dispersion of the drug. Processing variables therefore could significantly influence the solid-state of a drug in cyclodextrin-based formulations and thereby affect its dissolution behaviour. This could lead to significant effects on the in-vivo performance of the formulation.
我们研究了工艺变量对环糊精基体系中模型药物氟比洛芬固态的影响及其对药物溶出行为的作用。通过核磁共振光谱法和相溶解度研究考察了氟比洛芬与羟丙基-β-环糊精(HP-β-CyD)之间的相互作用。采用多种工艺制备了含氟比洛芬与HP-β-CyD或聚维酮(聚乙烯吡咯烷酮)K30的二元体系,通过傅里叶变换红外光谱(FTIR)、差示扫描量热法(DSC)、X射线衍射(XRD)和溶出度研究对其进行了表征。HP-β-CyD提高了氟比洛芬的溶解度,并提高了二元体系的溶出速率。结果发现,在产生更高溶出速率方面,它优于聚维酮K30。发现二元体系的制备方法和所用试剂对氟比洛芬的最终固态有重大影响。在制备过程中,有利于氟比洛芬与环糊精之间产生更强相互作用的溶剂和工艺条件会导致药物与环糊精的缔合程度更高和/或药物的非晶化程度更高。在二元体系制备过程中使用氨得到的固体,由于药物的分子分散程度更高,实现了药物的非常快速溶出。因此,工艺变量可显著影响基于环糊精的制剂中药物的固态,从而影响其溶出行为。这可能会对制剂的体内性能产生重大影响。